




Searching News Database: ulcerative colitis
HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
HSMN NewsFeed - 15 Feb 2021
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
HSMN NewsFeed - 24 Oct 2018
Inova Diagnostics Launches First FDA Cleared Calprotectin Extraction Device
Inova Diagnostics Launches First FDA Cleared Calprotectin Extraction Device
HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
HSMN NewsFeed - 3 Jan 2018
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
HSMN NewsFeed - 10 Aug 2015
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
HSMN NewsFeed - 8 Jul 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
HSMN NewsFeed - 13 Mar 2014
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
HSMN NewsFeed - 5 Jun 2013
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
HSMN NewsFeed - 22 May 2012
New Studies Confirm Given Imaging's PillCam(R) COLON 2's Feasibility in an Outpatient Setting
New Studies Confirm Given Imaging's PillCam(R) COLON 2's Feasibility in an Outpatient Setting
HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
HSMN NewsFeed - 3 Oct 2011
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
HSMN NewsFeed - 25 Mar 2010
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
HSMN NewsFeed - 28 Oct 2009
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
HSMN NewsFeed - 7 Oct 2009
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
HSMN NewsFeed - 15 Jun 2009
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
HSMN NewsFeed - 21 Oct 2008
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
HSMN NewsFeed - 9 Jul 2008
Study Shows That PillCam(R) SB Helps Doctors Treat Children With Crohn's Disease More Effectively
Study Shows That PillCam(R) SB Helps Doctors Treat Children With Crohn's Disease More Effectively
HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
HSMN NewsFeed - 19 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
HSMN NewsFeed - 27 Sep 2007
Asphelia Pharmaceuticals Appoints Francois-Xavier Frapaise As President and Chief Executive Officer
Asphelia Pharmaceuticals Appoints Francois-Xavier Frapaise As President and Chief Executive Officer
HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
HSMN NewsFeed - 17 Jul 2007
Aventir Biotech Launches New 510(k) Cleared Fecal Occult Blood Screen Test
Aventir Biotech Launches New 510(k) Cleared Fecal Occult Blood Screen Test
HSMN NewsFeed - 18 Jun 2007
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 29 Dec 2006
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Salix Pharmaceuticals Reports American College of Gastroenterology Update
HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
HSMN NewsFeed - 28 Sep 2006
Cerimon Pharmaceuticals Names Timothy J. McBride as Senior Vice President of Business Development
Cerimon Pharmaceuticals Names Timothy J. McBride as Senior Vice President of Business Development
HSMN NewsFeed - 26 Sep 2006
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
HSMN NewsFeed - 14 Sep 2006
BioBalance Announces the Resignation of Its CEO and the Assumption of Additional Duties by Richard Serbin
BioBalance Announces the Resignation of Its CEO and the Assumption of Additional Duties by Richard Serbin
HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
HSMN NewsFeed - 12 Jul 2006
Boston Scientific Launches Radial Jaw(R) 4, Newest Version of Single-Use Biopsy Forceps
Boston Scientific Launches Radial Jaw(R) 4, Newest Version of Single-Use Biopsy Forceps
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Additional items found! 120

Members Archive contains
120 additional stories matching:
ulcerative colitis
(Password required)
ulcerative colitis
(Password required)